Ru Feng

Department of Hematology, Southern Medical University

Affiliated withSouthern Medical University

Research Area

Biography

Ru Feng has not added Biography.
If you are Ru Feng and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
[Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA\| PubMed ID: 15567763	2004
[Transfection of human 293 and CD34+ cells with recombinant green fluorescent protein adeno- associated virus]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA\| PubMed ID: 15683991	2005
[Effects of graft compositions on hematopoietic reconstitution and graft-versus-host disease in related donor peripheral blood stem cell transplantation]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 18844073	2008
[Immunol reconstitution after autologous purified CD34+ cells transplantation in patients with systemic lupus erythematosus]. Zhonghua nei ke za zhi\| PubMed ID: 19080297	2008
Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a singl... Annals of hematology\| PubMed ID: 20872002	2011
[Clinical implications of HLA-G protein expression in acute leukemia]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University\| PubMed ID: 21097401	2010
Simultaneous analysis of telomere length and cell surface antigen in leukemia by multicolor Flow-FISH. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 21176337	2010
[Long-term outcomes of nilotinib treatment for chronic myelogenous leukemia patients with imatinib resistance or intolerance]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University\| PubMed ID: 22820586	2012
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression. Pharmacogenomics\| PubMed ID: 23252945	2013
Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation. PloS one\| PubMed ID: 23823695	2013
Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PloS one\| PubMed ID: 24124621	2013
Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leukemia research\| PubMed ID: 24713260	2014
The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression. Journal of hematology & oncology\| PubMed ID: 24739401	2014
Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation\| PubMed ID: 24769013	2014
[Research progress on minimal residual disease in acute leukemia detected by multiparametric flow cytometry]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 24989307	2014
[Effect of intermediate-dose cytarabine on mobilization of peripheral blood hematopoietic stem cell in acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\| PubMed ID: 25052597	2014
Lymphopenia predicts preclinical relapse in the routine follow-up of patients with diffuse large B-cell lymphoma. Leukemia & lymphoma\| PubMed ID: 25175043	2015
Lung MRI of invasive fungal infection at 3 Tesla: evaluation of five different pulse sequences and comparison with multidetector computed tomography (MDCT). European radiology\| PubMed ID: 25231132	2015
Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. Thrombosis research\| PubMed ID: 25747536	2015
The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PloS one\| PubMed ID: 25974110	2015
[Influence of L-asaraginase and Pegaspargase on Coagulation Function of Adult Patients with Acute Lymphoblastic Leukemia and Analysis of Related Factors]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 26913389	2016
Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung. European radiology\| PubMed ID: 27180185	2017
Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. International journal of hematology\| PubMed ID: 27393279	2016
The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP. Scientific reports\| PubMed ID: 29051524	2017
Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget\| PubMed ID: 29100345	2017
Biology of Tumor Associated Macrophages in Diffuse Large B Cell Lymphoma. DNA and cell biology\| PubMed ID: 30403536	2018
Publisher Correction: The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP. Scientific reports\| PubMed ID: 31053761	2019
Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma. International journal of hematology\| PubMed ID: 31993938	2020
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Journal of hematology & oncology\| PubMed ID: 32393328	2020
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 32461234	2020
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). Journal of hematology & oncology\| PubMed ID: 33436023	2021
Consecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma. Frontiers in oncology\| PubMed ID: 33585232	2020
Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. American journal of hematology\| PubMed ID: 33606900	2021
HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nature communications\| PubMed ID: 33782403	2021
LINC00908 Promotes Diffuse Large B-Cell Lymphoma Development by Down-Regulating miR-671-5p. Cancer management and research\| PubMed ID: 33958893	2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. Journal of hematology & oncology\| PubMed ID: 34649571	2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. Frontiers in oncology\| PubMed ID: 34804937	2021
Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma. Translational cancer research\| PubMed ID: 35116375	2021
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood\| PubMed ID: 35303070	2022
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition. Nature cancer\| PubMed ID: 35484420	2022
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic advances in hematology\| PubMed ID: 35510211	2022
CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma. Leukemia & lymphoma\| PubMed ID: 35819872	2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Advances in therapy\| PubMed ID: 35900694	2022
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. Leukemia & lymphoma\| PubMed ID: 36799536	2023
Validation of the imatinib-therapy failure model. Leukemia\| PubMed ID: 36973351	2023
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 37036990	2023
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. American journal of hematology\| PubMed ID: 37128776	2023
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractor... Investigational new drugs\| PubMed ID: 37420136	2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer medicine\| PubMed ID: 37705497	2023
Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort study. BMJ open\| PubMed ID: 38159939	2023
Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma. Aging\| PubMed ID: 38240686	2024
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal transduction and targeted therapy\| PubMed ID: 38755119	2024
Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010). Blood science (Baltimore, Md.)\| PubMed ID: 38832105	2024
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. Annals of hematology\| PubMed ID: 38888616	2024
Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma. Annals of hematology\| PubMed ID: 39222121	2024
A RANKL-UCHL1-sCD13 negative feedback loop limits osteoclastogenesis in subchondral bone to prevent osteoarthritis progression. Nature communications\| PubMed ID: 39389988	2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial. Journal for immunotherapy of cancer\| PubMed ID: 39455094	2024
Single-Cell Multiomics Reveals TCR Clonotype-Specific Phenotype and Stemness Heterogeneity of T-ALL Cells. Cell proliferation\| PubMed ID: 39675761	2025
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial. International journal of cancer\| PubMed ID: 40018797	2025
Correlation Between Fecal Microbiota and Corticosteroid Responsiveness in Primary Immune Thrombocytopenia: an Exploratory Study. Advanced science (Weinheim, Baden-Wurttemberg, Germany)\| PubMed ID: 40040609	2025
CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis. iScience\| PubMed ID: 40224025	2025
Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis. Advances in therapy\| PubMed ID: 40317419	2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study. Cancer communications (London, England)\| PubMed ID: 40344323	2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic ... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 40479620	2025
Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma. Immunobiology\| PubMed ID: 40639196	2025
Prognostic Performance of the FLAMB Model in Primary Gastric Diffuse Large B-Cell Lymphoma. British journal of hospital medicine (London, England : 2005)\| PubMed ID: 40847967	2025
The significance and role of the receptor and inflammatory factors in acute respiratory distress syndrome. Scientific reports\| PubMed ID: 41168271	2025